

AS. 158.776

Señora directora
DIRECCIÓN DE NUEVAS CREACIONES
SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO

RESPUESTA A OFICIO No. 22379 DEL 17 DE DICIEMBRE DE 2024

REF: Expediente No. NC2024/0012948 - Solicitud de Patente Fase Nacional
A favor de **NGM BIOPHARMACEUTICALS, INC.**
Titulada: AGENTES DE UNIÓN A ILT3 Y CD3 Y MÉTODOS DE USO DE ESTOS

JUAN PABLO CADENA SARMIENTO, vecino de Bogotá, portador de la tarjeta profesional No. 57492, obrando como apoderado de la sociedad **NGM BIOPHARMACEUTICALS, INC.**, según lo acredita el documento de poder presentado en esa Dirección, para dar cumplimiento al requerimiento notificado de manera automática el 18 de diciembre de 2024, de acuerdo con los Artículos 38 y 39 de la Decisión 486 de la comisión de la Comunidad Andina, me permito allegar:

1. Documento donde consta la cesión del derecho a la Patente otorgado por los inventores al solicitante.

De la señora directora atentamente,



JUAN PABLO CADENA SARMIENTO
C.C. No. 80.410.337 de Usaquén
T. P. 57.492 del Consejo Superior de la Judicatura

Bogotá, 15 de enero de 2025
JPC/jpg



013370-0172-228
Docketed 6/6/23
Tamera Weisser
Bing Liang
Amy Song

UNITED STATES PATENT AND TRADEMARK OFFICE

UNDER SECRETARY OF COMMERCE FOR INTELLECTUAL PROPERTY AND
DIRECTOR OF THE UNITED STATES PATENT AND TRADEMARK OFFICE

JUNE 5, 2023

PTAS

JONES DAY
250 VESEY STREET
ATTN: WENDY TOKMAKIDIS
NEW YORK, NY 10281

507939536

UNITED STATES PATENT AND TRADEMARK OFFICE NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT

THE ENCLOSED DOCUMENT HAS BEEN RECORDED BY THE ASSIGNMENT RECORDATION BRANCH OF THE U.S. PATENT AND TRADEMARK OFFICE. A COMPLETE COPY IS AVAILABLE AT THE ASSIGNMENT SEARCH ROOM ON THE REEL AND FRAME NUMBER REFERENCED BELOW.

PLEASE REVIEW ALL INFORMATION CONTAINED ON THIS NOTICE. THE INFORMATION CONTAINED ON THIS RECORDATION NOTICE REFLECTS THE DATA PRESENT IN THE PATENT AND TRADEMARK ASSIGNMENT SYSTEM. IF YOU SHOULD FIND ANY ERRORS OR HAVE QUESTIONS CONCERNING THIS NOTICE, YOU MAY CONTACT THE ASSIGNMENT RECORDATION BRANCH AT 571-272-3350. PLEASE SEND REQUEST FOR CORRECTION TO: U.S. PATENT AND TRADEMARK OFFICE, MAIL STOP: ASSIGNMENT RECORDATION BRANCH, P.O. BOX 1450, ALEXANDRIA, VA 22313.

RECORDATION DATE: 06/02/2023

REEL/FRAME: 063841/0599
NUMBER OF PAGES: 10

BRIEF: ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS).

DOCKET NUMBER: 13370-172-228

ASSIGNOR:
AKAMA, KEITH

DOC DATE: 05/30/2023

ASSIGNOR:
CHENG, RUJIN

DOC DATE: 05/31/2023

ASSIGNOR:
IYER, ANJUSHREE R.

DOC DATE: 05/31/2023

ASSIGNOR:
LIN, VICKY YI-BING

DOC DATE: 05/30/2023

ASSIGNOR:
RIVERA, LEE B.

DOC DATE: 05/30/2023

ASSIGNOR:
RODA, JULIE M.

DOC DATE: 05/30/2023

ASSIGNOR:
TANG, JIE

DOC DATE: 05/30/2023

ASSIGNOR:
YANG, HONG

DOC DATE: 05/30/2023

ASSIGNEE:
NGM BIOPHARMACEUTICALS, INC.
333 OYSTER POINT BOULEVARD
SOUTH SAN FRANCISCO, CALIFORNIA
94080

APPLICATION NUMBER: FILING DATE: 03/28/2023
PATENT NUMBER: ISSUE DATE:
PCT NUMBER: US2023065027
TITLE: ILT3 AND CD3 BINDING AGENTS AND METHODS OF USE THEREOF

ASSIGNMENT RECORDATION BRANCH
PUBLIC RECORDS DIVISION

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT7986671

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
KEITH AKAMA	05/30/2023
RUJIN CHENG	05/31/2023
ANJUSHREE R. IYER	05/31/2023
VICKY YI-BING LIN	05/30/2023
LEE B. RIVERA	05/30/2023
JULIE M. RODA	05/30/2023
JIE TANG	05/30/2023
HONG YANG	05/30/2023
RECEIVING PARTY DATA	
Name:	NGM BIOPHARMACEUTICALS, INC.
Street Address:	333 OYSTER POINT BOULEVARD
City:	SOUTH SAN FRANCISCO
State/Country:	CALIFORNIA
Postal Code:	94080
PROPERTY NUMBERS Total: 1	
Property Type	Number
PCT Number:	US2023065027
CORRESPONDENCE DATA	
Fax Number:	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Email:	wtokmakidis@jonesday.com, dtran@jonesday.com, amysong@jonesday.com
Correspondent Name:	JONES DAY
Address Line 1:	250 VESEY STREET
Address Line 2:	ATTN: WENDY TOKMAKIDIS
Address Line 4:	NEW YORK, NEW YORK 10281
ATTORNEY DOCKET NUMBER:	13370-172-228
NAME OF SUBMITTER:	DAI TRAN
SIGNATURE:	/Dai Tran/

ASSIGNMENT

WHEREAS, WE, **Keith Akama**, citizen of the United States, having a mailing address of 333 Oyster Point Boulevard, South San Francisco, California 94080 residing at San Francisco, California, **Rujin Cheng**, citizen of China, having a mailing address of 333 Oyster Point Boulevard, South San Francisco, California 94080 residing at Burlingame, California, **Anjushree R. Iyer**, citizen of India, having a mailing address of 333 Oyster Point Boulevard, South San Francisco, California 94080 residing at San Mateo, California, **Vicky Yi-Bing Lin**, citizen of the United States, having a mailing address of 333 Oyster Point Boulevard, South San Francisco, California 94080 residing at Cupertino, California, **Lee B. Rivera**, citizen of the United States, having a mailing address of 333 Oyster Point Boulevard, South San Francisco, California 94080 residing at Daly City, California, **Julie M. Roda**, citizen of the United States, having a mailing address of 333 Oyster Point Boulevard, South San Francisco, California 94080 residing at Pacifica, California, **Jie Tang**, citizen of the United States, having a mailing address of 333 Oyster Point Boulevard, South San Francisco, California 94080 residing at Palo Alto, California, and **Hong Yang**, citizen of the United States, having a mailing address of 333 Oyster Point Boulevard, South San Francisco, California 94080 residing at San Mateo, California, ASSIGNORS, are the inventors of the invention in **ILT3 AND CD3 BINDING AGENTS AND METHODS OF USE THEREOF** for which an international application has been filed under the Patent Cooperation Treaty.

- ☒ which is identified by Jones Day docket no. 13370-172-228
- ☒ which was filed on March 28, 2023, International Application No. PCT/US2023/065027

and WHEREAS, **NGM Biopharmaceuticals, Inc.**, a corporation organized and existing under the laws of the state of Delaware, and having an office for the transaction of business at 333 Oyster Point Boulevard, South San Francisco, California 94080, ASSIGNEE, is desirous of obtaining our entire right, title and interest in, to and under the said invention and the said application:

NOW, THEREFORE, for good and valuable consideration, the receipt of which is hereby acknowledged, we, the said ASSIGNORS, have sold, assigned, transferred and set over, and by these presents do hereby sell, assign, transfer and set over, unto the said ASSIGNEE, its successors, legal representatives and assigns, our entire right, title and interest in, to and under the said invention, and the said international application, all applications claiming benefit of priority from said international application, and all national stage applications of said international application, divisions, renewals and continuations thereof, and all Patents of the United States which may be granted thereon and all reissues and extensions thereof; and all applications for industrial property protection, including, without limitation, all applications for patents, utility models, and designs which may be filed for said invention in any country or countries, including countries foreign to the United States, together with the right to file such applications and the right to claim for the same the priority rights derived from said international application under the Patent Laws of the United States, the International Convention for the Protection of Industrial Property, or any other international agreement or the domestic laws of the country in which any such application is filed, as may be applicable; and all forms of industrial property protection, including, without limitation, patents, utility models, inventors' certificates and designs which may be granted for said invention in any country or countries foreign to the United States and all extensions, renewals and reissues thereof; and all right to sue for infringement including past infringement.

AND WE HEREBY authorize and request the Commissioner for Patents and any Official of any country or countries foreign to the United States, whose duty it is to issue patents or other evidence or forms of industrial property protection on applications as aforesaid, to issue the same to the said ASSIGNEE, its successors, legal representatives and assigns, in accordance with the terms of this instrument.

AND WE HEREBY covenant and agree that we have full right to convey the entire interest herein assigned, and that we have not executed, and will not execute, any agreement in conflict herewith.

AND WE HEREBY further covenant and agree that we will communicate to the said ASSIGNEE, its successors, legal representatives and assigns, any facts known to us respecting said invention, and testify in any legal proceeding, sign all lawful papers, execute all divisional, continuing, reissue and foreign applications, make all rightful oaths, and generally do everything possible to aid the said ASSIGNEE, its successors, legal representatives and assigns, to obtain and enforce proper protection for said invention in all countries.

IN TESTIMONY WHEREOF, We hereunto set our hands and seals the day and year set opposite our respective signatures.

[SIGNATURES BEGIN ON NEXT PAGE]

International Application No. PCT/US2023/065027

Date 5/30/2023, 2023

DocuSigned by:
Keith Akama L.S.
79B63E8D91C8497...

Date 5/31/2023, 2023

DocuSigned by:
Rujin Cheng L.S.
B5328E9203DC498...

Date 5/31/2023, 2023

DocuSigned by:
Anjushree R. Iyer L.S.
8B5A86DF58B114C8...

Date 5/30/2023, 2023

DocuSigned by:
Vicky Yi-Bing Lin L.S.
E986C80E9E0A466...

Date 5/30/2023, 2023

DocuSigned by:
Lee Rivera L.S.
0FEEFC85794E43E...

Date 5/30/2023, 2023

DocuSigned by:
Julie Roda L.S.
214C4DEF659A4434...

Date 5/30/2023, 2023

DocuSigned by:
Jie Tang L.S.
3236F5D54D424E0...

Date 5/30/2023, 2023

DocuSigned by:
Hong Yang L.S.
1A3A33B0F97A4C4...

ACCEPTED AND AGREED TO BY ASSIGNEE, **NGM Biopharmaceuticals, Inc.:**

Signature: Anthony Kuhlmann
2A5C22414FB04BF...

Date: 6/1/2023

Printed Name: Anthony C. Kuhlmann, Ph.D.

Title: Head of Intellectual Property

Certificate Of Completion

Envelope Id: BF39C8528C3E43A784A9B984D8D77F20

Status: Completed

Subject: Patent Assignment for signature re NGM936 (NP201-WO)

Source Envelope:

Document Pages: 2

Signatures: 9

Certificate Pages: 6

Initials: 0

AutoNav: Enabled

Enveloped Stamping: Enabled

Time Zone: (UTC-08:00) Pacific Time (US & Canada)

Envelope Originator:

Anthony Kuhlmann

333 Oyster Point

South San Francisco, CA 94085

akuhlmann@ngmbio.com

IP Address: 72.199.157.248

Record Tracking

Status: Original

5/30/2023 6:05:33 PM

Holder: Anthony Kuhlmann

akuhlmann@ngmbio.com

Location: DocuSign


Signer Events

Anjushree R. Iyer

aiyer@ngmbio.com

Security Level: Email, Account Authentication
(None)**Signature**

DocuSigned by:



8B5A86DF58D14C8...

Signature Adoption: Pre-selected Style

Using IP Address: 165.225.106.128

Timestamp

Sent: 5/30/2023 6:27:10 PM

Viewed: 5/31/2023 9:58:57 PM

Signed: 5/31/2023 10:00:48 PM

Electronic Record and Signature Disclosure:

Accepted: 5/31/2023 9:58:57 PM

ID: f56ee975-9c0f-4859-81ff-808c5e99604d

Hong Yang

hyang@ngmbio.com

Security Level: Email, Account Authentication
(None)

DocuSigned by:



1A3A3B0F97A4C4...

Signature Adoption: Pre-selected Style

Using IP Address: 104.129.192.197

Sent: 5/30/2023 6:27:11 PM

Viewed: 5/30/2023 7:43:36 PM

Signed: 5/30/2023 7:44:55 PM

Electronic Record and Signature Disclosure:

Accepted: 5/30/2023 7:43:36 PM


ID: 685585fb-9ff0-4d07-8ece-a36b88473d38

Jie Tang

jiemtang@gmail.com

Security Level: Email, Account Authentication
(None)

DocuSigned by:



3236F5D54D424E0...

Signature Adoption: Pre-selected Style

Using IP Address: 76.133.65.178

Sent: 5/30/2023 6:27:11 PM

Viewed: 5/30/2023 8:59:06 PM

Signed: 5/30/2023 8:59:26 PM

Electronic Record and Signature Disclosure:

Accepted: 5/30/2023 8:59:06 PM


ID: 866eed2f-6d2f-410f-a837-4dd1f8ca744e

Julie Roda

jroda@ngmbio.com

Security Level: Email, Account Authentication
(None)

DocuSigned by:



214CADE859A4434...

Signature Adoption: Pre-selected Style

Using IP Address: 24.6.186.53

Signed using mobile

Sent: 5/30/2023 6:27:12 PM






Viewed: 5/30/2023 6:53:18 PM

Signed: 5/30/2023 6:53:46 PM

Electronic Record and Signature Disclosure:

Accepted: 4/28/2023 1:53:11 PM

ID: 1e1af22c-9eae-4090-95e7-807c6c6b8697

Signer Events	Signature	Timestamp
Keith Akama keith.akama@gmail.com Security Level: Email, Account Authentication (None)	DocuSigned by:  7BB63E9D91C8497... Signature Adoption: Pre-selected Style Using IP Address: 73.231.129.80	Sent: 5/30/2023 6:27:13 PM Viewed: 5/30/2023 8:00:51 PM Signed: 5/30/2023 8:01:16 PM
Electronic Record and Signature Disclosure: Accepted: 5/30/2023 8:00:51 PM ID: 94adcbf3-8091-4daf-b4c0-19ba2d528093		
Lee Rivera lrivera@ngmbio.com Security Level: Email, Account Authentication (None)	DocuSigned by:  CFEFC85794E43E... Signature Adoption: Pre-selected Style Using IP Address: 67.169.106.37 Signed using mobile	Sent: 5/30/2023 6:27:13 PM Viewed: 5/30/2023 8:08:00 PM Signed: 5/30/2023 8:08:25 PM
Electronic Record and Signature Disclosure: Not Offered via DocuSign		
Rujin Cheng rcheng@ngmbio.com Security Level: Email, Account Authentication (None)	DocuSigned by:  BF328E9203DC498... Signature Adoption: Pre-selected Style Using IP Address: 76.20.59.223	Sent: 5/30/2023 6:27:13 PM Viewed: 5/31/2023 12:06:15 AM Signed: 5/31/2023 12:08:34 AM
Electronic Record and Signature Disclosure: Accepted: 5/31/2023 12:06:15 AM ID: 419ba10b-69b4-45aa-bfae-43ac1fee3f90		
Vicky Yi-Bing Lin Vicky.lin@gmail.com Security Level: Email, Account Authentication (None)	DocuSigned by:  D388C86E9EDA488... Signature Adoption: Pre-selected Style Using IP Address: 73.223.29.192	Sent: 5/30/2023 6:27:14 PM Resent: 5/30/2023 8:52:43 PM Viewed: 5/30/2023 9:00:26 PM Signed: 5/30/2023 9:01:28 PM
Electronic Record and Signature Disclosure: Accepted: 5/30/2023 9:00:26 PM ID: 52dff5e6-c219-458a-a5e4-f0d1928fa830		
Anthony Kuhlmann akuhlmann@ngmbio.com Head of Intellectual Property NGM Biopharmaceuticals, Inc. Security Level: Email, Account Authentication (None)	DocuSigned by:  2A5C22414F904BF... Signature Adoption: Pre-selected Style Using IP Address: 104.129.198.245	Sent: 5/31/2023 10:00:50 PM Viewed: 6/1/2023 5:18:20 PM Signed: 6/1/2023 5:18:34 PM
Electronic Record and Signature Disclosure: Not Offered via DocuSign		

In Person Signer Events	Signature	Timestamp
Editor Delivery Events	Status	Timestamp
Agent Delivery Events	Status	Timestamp
Intermediary Delivery Events	Status	Timestamp

Certified Delivery Events	Status	Timestamp
Carbon Copy Events	Status	Timestamp
Witness Events	Signature	Timestamp
Notary Events	Signature	Timestamp
Envelope Summary Events	Status	Timestamps
Envelope Sent	Hashed/Encrypted	5/30/2023 6:27:14 PM
Envelope Updated	Security Checked	5/30/2023 8:52:42 PM
Certified Delivered	Security Checked	6/1/2023 5:18:20 PM
Signing Complete	Security Checked	6/1/2023 5:18:34 PM
Completed	Security Checked	6/1/2023 5:18:34 PM
Payment Events	Status	Timestamps
Electronic Record and Signature Disclosure		

ELECTRONIC RECORD AND SIGNATURE DISCLOSURE

From time to time, NGM Biopharmaceuticals (we, us or Company) may be required by law to provide to you certain written notices or disclosures. Described below are the terms and conditions for providing to you such notices and disclosures electronically through the DocuSign, Inc. (DocuSign) electronic signing system. Please read the information below carefully and thoroughly, and if you can access this information electronically to your satisfaction and agree to these terms and conditions, please confirm your agreement by clicking the 'I agree' button at the bottom of this document.

Getting paper copies

At any time, you may request from us a paper copy of any record provided or made available electronically to you by us. You will have the ability to download and print documents we send to you through the DocuSign system during and immediately after signing session and, if you elect to create a DocuSign signer account, you may access them for a limited period of time (usually 30 days) after such documents are first sent to you. After such time, if you wish for us to send you paper copies of any such documents from our office to you, you will be charged a \$0.00 per-page fee. You may request delivery of such paper copies from us by following the procedure described below.

Withdrawing your consent

If you decide to receive notices and disclosures from us electronically, you may at any time change your mind and tell us that thereafter you want to receive required notices and disclosures only in paper format. How you must inform us of your decision to receive future notices and disclosure in paper format and withdraw your consent to receive notices and disclosures electronically is described below.

Consequences of changing your mind

If you elect to receive required notices and disclosures only in paper format, it will slow the speed at which we can complete certain steps in transactions with you and delivering services to you because we will need first to send the required notices or disclosures to you in paper format, and then wait until we receive back from you your acknowledgment of your receipt of such paper notices or disclosures. To indicate to us that you are changing your mind, you must withdraw your consent using the DocuSign 'Withdraw Consent' form on the signing page of a DocuSign envelope instead of signing it. This will indicate to us that you have withdrawn your consent to receive required notices and disclosures electronically from us and you will no longer be able to use the DocuSign system to receive required notices and consents electronically from us or to sign electronically documents from us.

All notices and disclosures will be sent to you electronically

Unless you tell us otherwise in accordance with the procedures described herein, we will provide electronically to you through the DocuSign system all required notices, disclosures, authorizations, acknowledgements, and other documents that are required to be provided or made available to you during the course of our relationship with you. To reduce the chance of you inadvertently not receiving any notice or disclosure, we prefer to provide all of the required notices and disclosures to you by the same method and to the same address that you have given us. Thus, you can receive all the disclosures and notices electronically or in paper format through the paper mail delivery system. If you do not agree with this process, please let us know as described below. Please also see the paragraph immediately above that describes the consequences of your electing not to receive delivery of the notices and disclosures electronically from us.

How to contact NGM Biopharmaceuticals:

You may contact us to let us know of your changes as to how we may contact you electronically, to request paper copies of certain information from us, and to withdraw your prior consent to receive notices and disclosures electronically as follows:

To contact us by email send messages to: jboucher@ngmbio.com

To advise NGM Biopharmaceuticals of your new e-mail address

To let us know of a change in your e-mail address where we should send notices and disclosures electronically to you, you must send an email message to us at jtran@ngmbio.com and in the body of such request you must state: your previous e-mail address, your new e-mail address. We do not require any other information from you to change your email address..

In addition, you must notify DocuSign, Inc. to arrange for your new email address to be reflected in your DocuSign account by following the process for changing e-mail in the DocuSign system.

To request paper copies from NGM Biopharmaceuticals

To request delivery from us of paper copies of the notices and disclosures previously provided by us to you electronically, you must send us an e-mail to jboucher@ngmbio.com and in the body of such request you must state your e-mail address, full name, US Postal address, and telephone number. We will bill you for any fees at that time, if any.

To withdraw your consent with NGM Biopharmaceuticals

To inform us that you no longer want to receive future notices and disclosures in electronic format you may:

- i. decline to sign a document from within your DocuSign session, and on the subsequent page, select the check-box indicating you wish to withdraw your consent, or you may;
- ii. send us an e-mail to jboucher@ngmbio.com and in the body of such request you must state your e-mail, full name, US Postal Address, and telephone number. We do not need any other information from you to withdraw consent.. The consequences of your withdrawing consent for online documents will be that transactions may take a longer time to process..

Required hardware and software

Operating Systems:	Windows® 2000, Windows® XP, Windows Vista®; Mac OS® X
Browsers:	Final release versions of Internet Explorer® 6.0 or above (Windows only); Mozilla Firefox 2.0 or above (Windows and Mac); Safari™ 3.0 or above (Mac only)
PDF Reader:	Acrobat® or similar software may be required to view and print PDF files
Screen Resolution:	800 x 600 minimum

Enabled Security Settings:	Allow per session cookies
----------------------------	---------------------------

** These minimum requirements are subject to change. If these requirements change, you will be asked to re-accept the disclosure. Pre-release (e.g. beta) versions of operating systems and browsers are not supported.

Acknowledging your access and consent to receive materials electronically

To confirm to us that you can access this information electronically, which will be similar to other electronic notices and disclosures that we will provide to you, please verify that you were able to read this electronic disclosure and that you also were able to print on paper or electronically save this page for your future reference and access or that you were able to e-mail this disclosure and consent to an address where you will be able to print on paper or save it for your future reference and access. Further, if you consent to receiving notices and disclosures exclusively in electronic format on the terms and conditions described above, please let us know by clicking the 'I agree' button below.

By checking the 'I agree' box, I confirm that:

- I can access and read this Electronic CONSENT TO ELECTRONIC RECEIPT OF ELECTRONIC RECORD AND SIGNATURE DISCLOSURES document; and
- I can print on paper the disclosure or save or send the disclosure to a place where I can print it, for future reference and access; and
- Until or unless I notify NGM Biopharmaceuticals as described above, I consent to receive from exclusively through electronic means all notices, disclosures, authorizations, acknowledgements, and other documents that are required to be provided or made available to me by NGM Biopharmaceuticals during the course of my relationship with you.